Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

被引：0
|
作者：
Zandberg, D. [1 ]
Algazi, A. [2 ]
Jimeno, A. [3 ,4 ,5 ]
Good, J. S. [6 ]
Fayette, J. [7 ]
Bouganim, N. [8 ]
Ready, N. [9 ]
Clement, P. M. [10 ]
Goswmi, T. [11 ]
Jarkowski, A. [11 ]
Armstrong, J. M. [11 ]
Asubonteng, K. [11 ]
Melillo, G. [11 ]
Mesia, R. [12 ]
机构：
[1] Univ Maryland, Greenebaum Comprehens Canc Ctr, Hematol Oncol, Baltimore, MD 21201 USA
[2] Univ Calif San Francisco, Oncol, San Francisco, CA 94143 USA
[3] Univ Colorado, Canc Ctr, Dept Med Oncol, Colorado City, CO USA
[4] Univ Colorado, Canc Ctr, Dept Otolaryngol, Colorado City, CO USA
[5] Gates Ctr Regenerat Med, Colorado City, CO USA
[6] Queen Elizabeth Hosp, Inst Head & Neck Studies & Educ, Oncol, Birmingham, W Midlands, England
[7] Univ Lyon, Canc Ctr Ctr Leon Berard, Clin Oncol, Lyon, France
[8] McGill Univ, Hlth Ctr, Dept Oncol, Montreal, PQ, Canada
[9] Duke Univ, Med Ctr, Med Oncol, Durham, NC USA
[10] Univ Hosp Leuven, Dept Oncol, Leuven, Belgium
[11] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[12] Univ Barcelona, Catalan Inst Oncol, Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
    Zandberg, D. P.
    Algazi, A.
    Jimeno, A.
    Good, J.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P.
    Goswami, T.
    Jarkowski, A.
    Armstrong, J.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 13 - 13
  • [2] VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
    Jove, M.
    Brana, I.
    Taberna, M.
    Hernando-Calvo, A.
    Brenes Castro, J.
    Garralda, E.
    Plana Serrahima, M.
    Manos Pujol, M.
    Capella, G.
    Alemany, R.
    Blasi, E.
    Blasco, C.
    Cascallo Piqueras, M.
    Nin, R. Mesia
    ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
  • [3] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Combination of anlotinib and sintilimab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: a single-arm prospective study
    Wang, Tianxiao
    Wang, Jiaxin
    Zhang, Yabing
    Song, Yuntao
    Xu, Guohui
    Zhang, Bin
    ANTI-CANCER DRUGS, 2025, 36 (01) : 79 - 84
  • [5] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [8] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [9] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
    Chung, Christine H.
    Bonomi, Marcelo Raul
    Steuer, Conor Ernst
    Schell, Michael J.
    Li, Jiannong
    Johnson, Matthew
    Masannat, Jude
    Hernandez-Prera, Juan C.
    McMullen, Caitlin
    Wadsworth, J.
    Patel, Krupal
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort
    Lynggaard, Charlotte Duch
    Therkildsen, Marianne Hamilton
    Kristensen, Claus Andrup
    Specht, Lena
    ACTA ONCOLOGICA, 2015, 54 (07) : 1071 - U151
12345